Scientists have urged policymakers to implement a regulatory framework governing the use of CRISPR technology in humans, following reports that a Chinese scientist has successfully created ‘edited’ twins.
The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Saul Ewing Arnstein & Lehr has strengthened its Boston office with the addition of two life sciences partners from Hamilton, Brook, Smith & Reynolds.
Genome sequencing company 10x Genomics has been accused of infringing 11 patents covering cell research and analysis tools.
Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb, does not need to pay damages despite being liable for trade secrets misappropriation.
HGF has strengthened its Basel, Switzerland office with the addition of Leena Contarino as a partner.
Gene-sequencing company Illumina has agreed to buy competitor Pacific Biosciences for $1.2 billion.
The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.
Siew Yen Chong has joined Nelson Mullins Riley & Scarborough’s New York office as of counsel.